We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current TRML market cap is 344.91M. The company's latest EPS is USD -2.0713 and P/E is -8.20.
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -24.08M | -16.5M | -8.97M | -3.42M | -17.52M |
Net Income | -22.5M | -14.74M | -7.02M | 2.13M | -13.31M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -18.38M | -22.68M | -47.51M | -76.48M | -45.41M |
Net Income | -18.16M | -22.71M | -47.83M | -73.89M | -42.12M |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 172.61M | 159.12M | 151.06M | 210.3M | 359.17M |
Total Liabilities | 10.88M | 10.69M | 8.19M | 5.25M | 5.03M |
Total Equity | 161.73M | 148.43M | 142.87M | 205.04M | 354.14M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 41.94M | 152.78M | 251.42M | 193.72M | 210.3M |
Total Liabilities | 2.35M | 4.77M | 8.61M | 13.66M | 5.25M |
Total Equity | -17.1M | -38.15M | 242.81M | 180.06M | 205.04M |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -16.9M | -31.58M | -39.1M | -28.08M | -14.92M |
Investing | 27.41M | 36.33M | 92.26M | 3.84M | -188.87M |
Financing | 46k | 183k | 257k | 156.72M | 161.35M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -17.66M | -19.21M | -39.99M | -60.86M | -28.08M |
Investing | -562k | -133.3M | -96.39M | 55.67M | 3.84M |
Financing | 36.2M | 131.12M | 137.4M | 242k | 156.72M |
Market Cap | 344.91M |
Price to Earnings Ratio | -8.20 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 2.45 |
Price to Book Ratio | 1.68 |
Dividend Yield | - |
Shares Outstanding | 20.34M |
Average Volume (1 week) | 343.01k |
Average Volume (1 Month) | 288.73k |
52 Week Change | 64.34% |
52 Week High | 48.31 |
52 Week Low | 9.18 |
Spread (Intraday) | 3.17 (15.75%) |
Company Name | Tourmaline Bio Inc |
Address |
251 little falls drive wilmington, delaware 19808 |
Website | https://talaristx.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions